NEW YORK (GenomeWeb News) – Integrated Diagnostics has licensed technology from The Scripps Research Institute that it will use to create new site-specific binding molecules to be attached to targeted proteins, the company said today.
Under the agreement, Integrated Diagnostics will use Scripps' click chemistry technology, which enables scientists to permanently join together molecular components with "unusual precision and stability," according to the Seattle-based company, founded by Lee Hood in 2009.
The firm is developing diagnostics for biomarker selection and a new class of synthetic diagnostic and therapeutic agents with antibody-like properties called protein-catalyzed capture agents (PCCs), which the company said in a separate release today that it developed through a collaboration with researchers at the California Institute of Technology.
Integrated Diagnostics plans to use the click chemistry to develop PCCs for use in new diagnostic and therapeutic applications.
"Click chemistry allows us to craft site-specific binding molecules that neatly 'click' onto the targeted protein where they have self-assembled on the target's surface," Integrated Diagnostics CEO Al Luderer said in a statement. "In this way, the process – which is synthetic and highly scalable – is 'directed' by the actual site targeted. The resulting molecule is highly stable, both on the shelf and in vivo."
Financial terms of the licensing agreement were not released.